ClinicalTrials.gg
CompletedNCT05891496Updated Aug 18, 2026Results posted

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

A Phase 3 interventional study of Semaglutide and Placebo in Alzheimers Disease, sponsored by Novo Nordisk A/S. Completed at 12 sites in 6 countries. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Alzheimer Disease with a site in Italy — 54 open to participants now, 73 under way, 19 of them phase 3. Alzheimer Disease · Italy.

Enrollment
162nd of 170
23 · median 328
Started
2023
with 15 others
Phase 3
67 of 206
10 open now
Registered
136th of 206
by date

Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 162nd largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2023, is one of 67 in phase 3, and was the 136th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Alzheimer Disease with a site in Italy, or all of them as a file.
02

Study summary

The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight. This study will help us understand whether semaglutide can also be used for the treatment of Alzheimer's disease. The study will last for about 77 weeks. In the first 12 weeks of treatment, participants will either get semaglutide (active medicine) or placebo (inactive dummy medicine). Which treatment participants get is decided by chance. In the following 52 weeks of treatment, all participants taking part in the study will get semaglutide. Participants must have a study partner, who is willing to take part in the study. Participants will get study medicine in a pen injector. The study partner will need to inject the study medicine into the skin of participant's stomach, thigh or upper arm once every week.

03

Conditions studied

  • Alzheimers Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 55-75 years (both inclusive) at the time of signing the
  • Mild cognitive impairment (MCI) or mild dementia of the Alzheimer's type according to the National Institute on Aging- Alzheimer's Association (NIA-AA) 2018 criteria
  • Clinical dementia rating (CDR) global score of 0.5 or 1 at screening (visit 1)
  • Amyloid positivity established with either historical amyloid positron emission tomography (PET) or historical cerebrospinal fluid (CSF) Aβ1-42 or historical CSF Aβ1-42/Aβ1-40 (historical data within the last 5 years) or blood sample for amyloid biomarker (Aβ42/Aβ40 ratio and p-tau217/np-tau217 ratio) at screening (visit 1)
  • Treated with acetylcholinesterase inhibitors (approved for the treatment of Alzheimer's disease) and on stable dose for greater than 90 days before screening (visit 1)

Exclusion criteria

Exclusion Criteria:

  • Brain magnetic resonance imaging (MRI) scan suggestive of structural central nervous system (CNS) disease confirmed by local read (example cerebral large-vessel disease [large vessel (cortical) infarcts greater than 10 millimeter (mm) in diameter], prior macro-haemorrhage [greater than 1centimeter cube (cm\^3)], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus)
  • Brain MRI scan suggestive of significant small vessel pathology confirmed by local read and defined as greater than 1 lacunar infarct and/or white matter hyperintensity (WMH) Fazekas13 scale greater than 2, (white matter [WM] greater than 20 mm) in the deep white matter and periventricular regions
  • History or evidence of diseases such as inflammatory bowel disease, rheumatoid arthritis, lupus, glomerulonephritis, psoriasis (but not limited to): Any other medical condition that would require use of systemic or or immunostimulants in the 12 months prior to screening (visit 1)
  • Received a vaccine product (including booster) 4 weeks prior to screening (visit 1) or expected to receive a vaccine product (including booster) before visit 5
  • Use of any systemic immunomodulating drugs (small molecules and/or biologics) in the last 12 months prior to screening (visit 1) or anticipated use of such drugs during study intervention period 1 (i.e., during the first 12 weeks of treatment until visit 5), such as corticosteroids for systemic use, immunostimulants and immunosuppressants
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Study intervention period 1

    Participants will receive either semaglutide or placebo matched to semaglutide once-weekly subcutaneous (s.c.) injections for 12 weeks as an add on therapy to standard of care. Participants initially received 0.25 milligram (mg) once weekly and the dose was then escalated once in 4 weeks until the maintenance dose (1.0 mg) was reached: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 12).

    Drug: Semaglutide · Drug: Placebo

  • Placebo comparator
    Study intervention period 2

    All participants will receive 1.0 mg semaglutide s.c. injections once weekly for 52 weeks during study intervention period 2 as an add-on therapy to standard of care. Participants randomised to semaglutide s.c. 1.0 mg during study intervention period 1 remained on 1.0 mg target maintenance dose for 52 weeks from weeks 12-64. Participants initially randomised to placebo during study intervention period 1 will receive semaglutide s.c. in dose escalation fashion for 8 weeks (0.25 mg from weeks 12-16 and 0.5 mg from weeks 16-20) followed by a maintenance period from weeks 20-64 at dose 1.0 mg.

    Drug: Semaglutide

Interventions

  • Semagllutide will be administered once weekly subcutaneously.

  • DrugPlacebo

    Placebo matched to semaglutide will be administered once weekly subcutaneously.

06

What researchers measure

Primary outcomes

  1. Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF])

    Change in gene expression assessed by scRNAseq (cells in CSF) from baseline (week 0) to week 12 is presented. Change in gene expression is presented as the mean number of differentially expressed genes (DEG).

    Time frame: Baseline (week 0), week 12

  2. Change in Gene Expression Assessed by scRNAseq (Cells in Blood)

    Change in gene expression assessed by scRNAseq (cells in blood) from baseline (week 0) to week 12 is presented. Change in gene expression is presented as the mean number of differentially expressed genes.

    Time frame: Baseline (week 0), week 12

Secondary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. All AEs mentioned here are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment period.

    Time frame: From baseline (week 0) to week 12

  2. Number of TEAEs

    Time frame: From baseline (week 0) to week 64

  3. Weekly Average Semaglutide Concentration [Average Concentration (Cavg)] Based on Population Pharmacokinetics (PK) Analysis

    Time frame: From week 4 to week 64

07

Results

Posted Feb 24, 2026

Participant flow

The trial was conducted at 7 sites in 5 countries (Canada, Denmark, Sweden, Switzerland and the United States).

Period 1: 12 Weeks
Participant flow — Period 1: 12 Weeks
MilestoneSemaglutidePlaceboPlacebo to Semaglutide
Started11120
Full analysis set11120
Safety analysis set11120
Completed11120
Not completed000
Period 2: 52 Weeks
Participant flow — Period 2: 52 Weeks
MilestoneSemaglutidePlaceboPlacebo to Semaglutide
Started11012
Treated10012
Completed000
Not completed11012
Withdrew: Ongoing10012
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryChange in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF])

Change in gene expression assessed by scRNAseq (cells in CSF) from baseline (week 0) to week 12 is presented. Change in gene expression is presented as the mean number of differentially expressed genes (DEG).

Time frame:
Baseline (week 0), week 12
Reported as:
Mean · Differentially expressed genes
Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF])
Differentially expressed genesSemaglutidePlacebo
Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF])41.25 ± 29.6821.00 ± 25.70
PrimaryChange in Gene Expression Assessed by scRNAseq (Cells in Blood)

Change in gene expression assessed by scRNAseq (cells in blood) from baseline (week 0) to week 12 is presented. Change in gene expression is presented as the mean number of differentially expressed genes.

Time frame:
Baseline (week 0), week 12
Reported as:
Mean · Differentially expressed genes
Change in Gene Expression Assessed by scRNAseq (Cells in Blood)
Differentially expressed genesSemaglutidePlacebo
Change in Gene Expression Assessed by scRNAseq (Cells in Blood)10.00 ± 5.9716.50 ± 15.86
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. All AEs mentioned here are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment period.

Time frame:
From baseline (week 0) to week 12
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsSemaglutidePlacebo
Number of Treatment Emergent Adverse Events (TEAEs)318
SecondaryNumber of TEAEs
Time frame:
From baseline (week 0) to week 64

Results for this outcome have not been posted.

SecondaryWeekly Average Semaglutide Concentration [Average Concentration (Cavg)] Based on Population Pharmacokinetics (PK) Analysis
Time frame:
From week 4 to week 64

Results for this outcome have not been posted.

Adverse events

Collected over From baseline (week 0) to end of study (week 69). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide Period 10/11 (0%)0/11 (0%)9/11 (81.8%)
Placebo0/12 (0%)0/12 (0%)5/12 (41.7%)
Semaglutide Period 21/22 (4.5%)1/22 (4.5%)15/22 (68.2%)
Most frequent serious events
Most frequent serious events
EventSemaglutide Period 1PlaceboSemaglutide Period 2
Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/110/121/22
Most frequent other events
Showing 10 of 22
Most frequent other events
EventSemaglutide Period 1PlaceboSemaglutide Period 2
Weight decreasedInvestigations5/111/126/22
Decreased appetiteMetabolism and nutrition disorders4/110/125/22
NauseaGastrointestinal disorders4/111/127/22
Abdominal pain upperGastrointestinal disorders2/110/120/22
DyspepsiaGastrointestinal disorders2/110/121/22
FatigueGeneral disorders2/110/121/22
NasopharyngitisInfections and infestations2/110/122/22
CatarrhRespiratory, thoracic and mediastinal disorders1/110/120/22
ConstipationGastrointestinal disorders1/110/121/22
DizzinessNervous system disorders1/110/120/22

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)SemaglutidePlaceboTotal
Mean65.8 ± 5.469.3 ± 4.167.6 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)SemaglutidePlaceboTotal
Female7815
Male448
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SemaglutidePlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino111223
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SemaglutidePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White111223
More than one race000
Unknown or Not Reported000
08

Study locations

12 sites
  • Banner Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • Brain Matters Research
    Delray Beach, Florida 33445, United States
  • Ottawa Memory Clinic
    Ottawa, Ontario K1Z 1G3, Canada
  • Memory Program
    Toronto, Ontario M3B2S7, Canada
  • Rigshospitalet - afsnit 8015 Hukommelsesklinikken
    København Ø, 2100, Denmark
  • Rigshospitalet - afsnit 8015
    København Ø, 2100, Denmark
  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia
    Perugia, 06132, Italy
  • Azienda Ospedaliera di Perugia;Ospedale S. Maria della Miser
    Perugia, 06132, Italy
  • Fondazione Santa Lucia IRCCS
    Roma, 00179, Italy
  • Karolinska Universitetssjukhuset, Huddinge
    Stockholm, 141 86, Sweden
  • Centre de la Mémoire
    Geneva, 1205, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2024, 13 months.

Results were first posted in Feb 2026, 1 year 6 months after primary completion.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 13 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2023
First posted
Jun 7, 2023
StartActual
Jun 20, 2023
Primary completionActual
Aug 19, 2024
CompletionActual
Sep 8, 2025
Results first posted
Feb 24, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05891496
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 7, 2023
Start date
Jun 20, 2023
Primary completion
Aug 19, 2024
Completion
Sep 8, 2025
Results posted
Feb 24, 2026
Last update
Aug 18, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion